
    
      'This is a Phase II, open-label, non-randomized, multi-center study assessing the efficacy
      and safety of Olaparib maintenance with Bevacizumab and Pembrolizumab in subjects with
      platinum-sensitive who have received prior of platinum-based chemotherapy. The study will
      assess the effectiveness of progression-free survival(6 months PFS rate) as determined by
      Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The subject will be treated to
      until disease progression as below:

        -  Maintenance : Olaparib 300mg (twice daily [BID])

        -  Pembrolizumab 200mg every 3 weeks (Q3W) from 2nd infusion for up to 35 infusions

        -  Bevacizumab 15mg/kg or 7.5mg/kg every 3 weeks (Q3W)
    
  